S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
OTCMKTS:PMCUF

Pro Medicus Stock Forecast, Price & News

$39.40
-2.24 (-5.38%)
(As of 12/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$39.40
$39.99
50-Day Range
$37.89
$46.11
52-Week Range
$22.00
$48.81
Volume
375 shs
Average Volume
873 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive PMCUF News and Ratings via Email

Sign-up to receive the latest news and ratings for Pro Medicus and its competitors with MarketBeat's FREE daily newsletter.


Pro Medicus logo

About Pro Medicus

Pro Medicus Limited provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualization solutions in Australia, Europe, and North America. It offers medical software for practice management; integration products; Promedicus.net secure email; healthcare software that provides radiologist and clinicians with advanced visualization capability for viewing 2-D, 3-D, and 4-D medical images; and PACS/Digital imaging software. The company offers its products under the Visage RIS, Visage RIS/PACS, and Visage 7 names. It also provides Visage Ease Pro, a mobile applications, which allow users access to medical imaging results that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company offers its products and services to hospitals, diagnostic imaging groups, and other health related entities. Pro Medicus Limited was founded in 1983 and is headquartered in Richmond, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Health Information Services
Sub-Industry
N/A
Current Symbol
OTCMKTS:PMCUF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.33 out of 5 stars

Analyst Opinion: 2.7Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Pro Medicus (OTCMKTS:PMCUF) Frequently Asked Questions

Is Pro Medicus a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pro Medicus in the last twelve months. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" Pro Medicus stock.
View analyst ratings for Pro Medicus
or view top-rated stocks.

How has Pro Medicus' stock been impacted by Coronavirus (COVID-19)?

Pro Medicus' stock was trading at $11.69 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PMCUF shares have increased by 237.0% and is now trading at $39.40.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Pro Medicus?

Pro Medicus saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 7,300 shares, a decrease of 22.3% from the October 31st total of 9,400 shares. Based on an average daily volume of 500 shares, the short-interest ratio is presently 14.6 days.
View Pro Medicus' Short Interest
.

What price target have analysts set for PMCUF?

3 Wall Street analysts have issued 1-year price targets for Pro Medicus' shares. Their forecasts range from $54.00 to $54.00. On average, they expect Pro Medicus' share price to reach $54.00 in the next year. This suggests a possible upside of 37.1% from the stock's current price.
View analysts' price targets for Pro Medicus
or view top-rated stocks among Wall Street analysts.

Who are Pro Medicus' key executives?

Pro Medicus' management team includes the following people:
  • Dr. Sam Aaron Hupert M.D., M.B.B.S., Co-Founder, CEO, MD & Exec. Director
  • Mr. Anthony Barry Hall B.Sc., B.Sc.(Hons), M.Sc., Co-Founder, Technology Director & Exec. Director
  • Dr. Malte Westerhoff, GM of Europe & Global CTO
  • Mr. Brad Levin, GM of North America & Global Head of Marketing
  • Mr. Sean Lambright, Global Head of Sales - Visage Imaging Inc
  • Mr. Clayton James Hatch CPA, B.Comm, CPA, CFO & Company Sec.

What is Pro Medicus' stock symbol?

Pro Medicus trades on the OTCMKTS under the ticker symbol "PMCUF."

How do I buy shares of Pro Medicus?

Shares of PMCUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pro Medicus' stock price today?

One share of PMCUF stock can currently be purchased for approximately $39.40.

What is Pro Medicus' official website?

The official website for Pro Medicus is www.promed.com.au.

Where are Pro Medicus' headquarters?

Pro Medicus is headquartered at 450 Swan Street, Richmond, Victoria (VIC).

How can I contact Pro Medicus?

Pro Medicus' mailing address is 450 Swan Street, Richmond, Victoria (VIC). The company can be reached via phone at 61 3 9429 8800.


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.